ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
ARVINAS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$7.26+0.29 (+4.16%)
Close on Oct 19, 2026
- Market cap
- $476.98M
- P/E (TTM)
- 45.4
- Dividend yield
- –
Share price
−$2.26 (−23.74%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ARVINAS, INC. saw revenue fall 15.0% to $316.70M over the twelve months to Jun 30, 2026. Free cash flow was -$208.80M.
Revenue
$316.70M
-15.0% vs. a year earlier
Operating income
-$18.10M
TTM Q2 2026
Free cash flow
-$208.80M
TTM Q2 2026
EPS, diluted
$0.16
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $476.98M
- P/E ratio
- 45.4
- Price to sales
- 1.51
- Price to book
- 0.85
- Dividend yield
- –
- Free cash flow yield
- -43.78%
Fundamentals
- Revenue
- $316.70M
- Net income
- $9.30M
- EPS, diluted
- $0.16
- Free cash flow
- -$208.80M
- Book value per share
- $8.56
- Diluted shares
- 66M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$316.70M-15.0% YoY
Operating income
-$18.10M
Net income
$9.30M
EPS, diluted
$0.16
Free cash flow
-$208.80M
Reported periodTrailing twelve months